Table 1 Clinical characteristics of the multimodal cohort and the subset of patients with a complete multimodal profile

From: Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer

Clinical characteristics

Multimodal cohort (n = 317)

Immuno + chemo (n = 196)

Immuno alone (n = 121)

Subset with all modalities (n = 80)

Statistical comparison (80 vs 237)

Age – median (range)

66 (33-92)

64 (33-84)

69 (40-92)

64 (37-82)

\({p}_{{val}}^{1}=\) 4.9e-3

Sex - n (%)

Men

189 (60)

113 (58)

76 (63)

46 (57)

\({p}_{{val}}^{2}=\) 6.0e-1

Women

128 (40)

83 (42)

45 (37)

34 (43)

1st line therapy – n (%)

Pembrolizumab + chemotherapy

196 (62)

196 (100)

–

55 (69)

\({p}_{{val}}^{2}=\) 9.2e-2

Pembrolizumab

121 (38)

–

121 (100)

25 (31)

Histology - n (%)

Adenocarcinomas

232 (73)

152 (77)

80 (66)

54 (68)

\({p}_{{val}}^{2}=\) 2.8e-2

Squamous cell carcinomas

44 (14)

17 (9)

27 (22)

13 (16)

Other subtypes/not available

41 (13)

27 (14)

14 (12)

13 (16)

PD-L1 expression – n (%)

≥ 50%

163 (51)

49 (25)

114 (94)

42 (52)

\({p}_{{val}}^{2}=\) 6.2e-1

1–49%

82 (26)

78 (40)

4 (3)

23 (29)

Negative

56 (18)

56 (29)

0 (0)

11 (14)

Not available

16 (5)

13 (6)

3 (3)

4 (5)

Smoking status – n (%)

Current/former

287 (91)

180 (92)

107 (88)

71 (89)

\({p}_{{val}}^{2}=\) 6.9e-1

Never

29 (9)

15 (8)

14 (12)

8 (10)

Not available

1 (< 1)

1 (< 1)

0 (0)

1 (1)

Performance status – n (%)

ECOG 0/1

244 (77)

158 (81)

86 (71)

71 (89)

\({p}_{{val}}^{2}=\) 1.5e-3

ECOG ≥ 2

36 (11)

14 (7)

22 (18)

1 (1)

Not available

37 (12)

24 (12)

13 (11)

8 (10)

TILs – n (%)

Positive

159 (50)

82 (42)

77 (64)

49 (61)

\({p}_{{val}}^{2}=\) 2.8e-2

Negative

18 (6)

9 (5)

9 (7)

3 (4)

Not available

140 (44)

105 (53)

35 (29)

28 (35)

Median Overall Survival – days (95% CI)

756 (592–910)

723 (446–987)

763 (576-NR)

846 (650-NR)

\({p}_{{val}}^{3}=\) 2.7e-1

Median Progression Free Survival – days (95% CI)

296 (241–372)

301 (145–598)

290 (241–372)

386 (275–711)

\({p}_{{val}}^{3}=\) 1.6e-2

  1. ECOG Eastern Cooperative Oncology Group, TILs Tumor-Infiltrating Lymphocytes, NR Not Reached, \({p}_{{val}}^{1}\) Welch’s t test p-value - \({p}_{{val}}^{2}\) Chi-squared test p-value - \({p}_{{val}}^{3}\) Log-rank test p-value.
  2. The results of the statistical comparison between the subset of patients with a complete profile and the rest of the cohort, using two-sided Welch’s t tests, one-way Chi-squared tests, and Log-rank tests, are presented in the last column.
Back to article page